The other thing Karst Peak assumes is a 10x cash flow multiple for Trof "giving consideration to patent life and paediatric orphan drug exclusivity". Out of curiosity, is there a reason you are using 25x crem? Or more broadly is there a reason NEU might get the advantage longer than c.10 years?
The other thing Karst Peak assumes is a 10x cash flow multiple...
-
- There are more pages in this discussion • 1,632 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.01 |
Change
-0.010(0.08%) |
Mkt cap ! $1.662B | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.26 | $12.81 | $5.865M | 451.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14541 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.02 | 2438 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |